Literature DB >> 16266909

High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma.

Stéphane Vigouroux, Fanny Gaillard, Philippe Moreau, Jean-Luc Harousseau, Noël Milpied.   

Abstract

We retrospectively investigated the outcome of 30 newly diagnosed patients with mantle cell lymphoma treated with high-dose therapy and autologous stem cell transplantation in first response. With a median follow-up of 55 months, the 5-year overall-survival is 62%, the 5-year progression-free-survival is 40% and no secondary malignancy has occurred.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16266909

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  7 in total

1.  Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma.

Authors:  Peter A Riedell; Mehdi Hamadani; Kwang W Ahn; Carlos Litovich; Guru Subramanian Guru Murthy; Frederick L Locke; Claudio G Brunstein; Reid W Merryman; Patrick J Stiff; Attaphol Pawarode; Taiga Nishihori; Mohamed A Kharfan-Dabaja; Alex F Herrera; Craig S Sauter; Sonali M Smith
Journal:  Transplant Cell Ther       Date:  2021-08-24

2.  Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.

Authors:  A Goy; S H Bernstein; B S Kahl; B Djulbegovic; M J Robertson; S de Vos; E Epner; A Krishnan; J P Leonard; S Lonial; S Nasta; O A O'Connor; H Shi; A L Boral; R I Fisher
Journal:  Ann Oncol       Date:  2008-12-12       Impact factor: 32.976

3.  Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma.

Authors:  Brian G Till; Theodore A Gooley; Nathan Crawford; Ajay K Gopal; David G Maloney; Stephen H Petersdorf; John M Pagel; Leona Holmberg; William Bensinger; Oliver W Press
Journal:  Leuk Lymphoma       Date:  2008-06

Review 4.  Frontline Treatment for Older Patients with Mantle Cell Lymphoma.

Authors:  Haige Ye; Aakash Desai; Dongfeng Zeng; Jorge Romaguera; Michael L Wang
Journal:  Oncologist       Date:  2018-06-12

5.  Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study.

Authors:  Eric D Hsi; Sin-Ho Jung; Raymond Lai; Jeffrey L Johnson; James R Cook; Dan Jones; Sven Devos; Bruce D Cheson; Lloyd E Damon; Jonathan Said
Journal:  Leuk Lymphoma       Date:  2008-11

6.  Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.

Authors:  Constantine S Tam; Roland Bassett; Celina Ledesma; Martin Korbling; Amin Alousi; Chitra Hosing; Partow Kebraei; Robyn Harrell; Gabriela Rondon; Sergio A Giralt; Paolo Anderlini; Uday Popat; Barbara Pro; Barry Samuels; Frederick Hagemeister; L Jeffrey Medeiros; Richard E Champlin; Issa F Khouri
Journal:  Blood       Date:  2009-01-23       Impact factor: 22.113

7.  Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study.

Authors:  Xiao-Xiao Wang; Yan Gao; Jie Jin; Jun-Ning Cao; Ji-Feng Feng; Hua-Qing Wang; Hui-Lai Zhang; Qing-Qing Cai; Zhi-Ming Li; Wen-Qi Jiang; Hui-Qiang Huang
Journal:  Ann Hematol       Date:  2021-07-31       Impact factor: 3.673
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.